The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis

Shin Young Kim, Hye Min Moon, Min Kyoung Lee, Youn Jee Chung, Jae Yen Song, Hyun Hee Cho, Mee Ran Kim, Jang Heub Kim

Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea

Objective
We compared the expression levels of Müllerian inhibiting substance (MIS)/anti-Müllerian hormone type II receptor (AMHRII) in uterine myoma and adenomyosis to evaluate the possibility of using MIS/anti-Müllerian hormone (AMH) as a biological regulator or therapeutic agent in patients with uterine leiomyoma and adenomyosis.

Methods
We studied normal uterine myometrium, leiomyoma, endometrial tissue, and adenomyosis from 57 patients who underwent hysterectomy for uterine leiomyoma (22 cases) or adenomyosis (28 cases) and myomectomy for uterine myoma (7 cases). Immunohistochemical staining was used to confirm the MIS/AMHRII protein expression level in each tissue. Reverse transcription-polymerase chain reaction was performed to quantify MIS/AMHRII mRNA expression.

Results
The MIS/AMHRII protein was more strongly expressed in uterine myoma (frequency of MIS/AMHRII expressing cells: 51.95%±13.96%) and adenomyosis (64.65%±4.85%) tissues than that in the normal uterine myometrium (3.15%±1.69%) and endometrium (31.10%±7.19%). In the quantitative analysis of MIS/AMHRII mRNA expression, MIS/AMHRII mRNA expression levels in uterine myoma (mean density: 4.51±0.26) and adenomyosis (6.84±0.20) tissues were higher than that in normal uterine myometrial tissue (0.08±0.09) and endometrial tissue (1.63±0.06).

Conclusion
This study demonstrated that MIS/AMHRII was highly and strongly expressed on uterine myoma and adenomyosis. Our data suggest that MIS/AMH may be evaluated as a biological modulator or therapeutic agent on MIS/AMHRII expressing uterine myoma and adenomyosis.

Keywords: Adenomyosis; Anti-Müllerian hormone; Anti-Müllerian hormone receptor; Myoma

Introduction
Müllerian inhibiting substance (MIS) is known as anti-Müllerian hormone (AMH) and was named in 1946 when Alfred Jost discovered that a molecule, which was not testosterone and secreted from the rabbit embryonic testis, degenerated the Müllerian duct [1]. This hormone is a 140 kDa glycoprotein composed of 545 amino acids that belongs to the multigene family of transforming growth factor-beta (TGF-β) [2]. The Müllerian duct develops into the fallopian tube, uterus, cervix, proximal part of the vagina, and ovarian epithelium in women. MIS/AMH, which is produced at a high concentration in fetal
testis, binds to the MIS/AMH receptor of the primordial Müllerian duct and suppresses development of female genitalia in boys; thus, playing an important role in sexual development [3,4]. In female, MIS/AMH is produced by the granulosa cells of ovary and is secreted into the follicular fluid and serum [5-8]. MIS/AMH appears at the end of the third trimester of pregnancy about 36 weeks of gestation and is rarely detectable at birth and reaches the highest values after puberty [5-8]. After menopause, secretion decreases, so it has also been used as a measure of the degree of loss of ovarian function [5-8].

MIS/AMH not only plays an important role in fetal sexual development, but also inhibits growth of tumors originating from the Müllerian duct where the MIS/AMH receptor is expressed [9-11], such as ovarian [12-17], cervical [18-21], and endometrial cancers [22,23]. Masiakos et al. [14] reported that MIS/anti-Müllerian hormone type II receptor (AMHRII) is expressed at a high frequency in cells detected in ascites of patients with stage III/IV ovarian cancer, and MIS/AMH cause the growth inhibition of ovarian cancer cells expressing the MIS/AMH receptor. Similarly, Barbie et al. [21] reported that MIS/AMHRII is expressed in a number of cervical cancer cell lines and that MIS/AMH inhibits growth of cervical cancer cells. In addition to inhibiting malignant tumors, MIS/AMH also inhibits benign diseases originating from the Müllerian duct, such as endometrial stromal cells in endometriosis [24].

Uterine leiomyoma is the most common tumor of the female reproductive tract and is a monoclonal myometrial tumor originating from the Müllerian duct [25,26]. Adenomyosis is a disease in which the endometrial tissue invades the myometrium resulting in a diffusely enlarged uterus [27]. Both are benign uterine diseases of Müllerian duct origin, and they are very common in women of childbearing age. However, unlike malignant diseases, few studies have investigated MIS/AMHRII expression in myoma and adenomyosis.

In this study, we investigated MIS/AMHRII expression levels in uterine myoma and adenomyosis tissues to evaluate the possibility of using MIS/AMH as a potential therapeutic modality via receptor-mediated mechanism in uterine myoma and adenomyosis.

**Materials and methods**

1. **Study objectives**

We included 57 women who underwent myomectomy for uterine myoma (7 cases) or total hysterectomy for uterine myoma (22 cases) or adenomyosis (28 cases) from March 2016 to October 2016 at Uijeongbu St. Mary’s Hospital. The patients were explained the objectives of study and informed consent was obtained from all participants. We examined 22 myometria, 29 uterine myomas, 28 endometria, and 28 adenomyosis tissue samples confirmed by a pathologist. In myomectomy, the extraction of normal muscle tissue may cause unnecessary injury to the uterus. Thus, normal muscle tissue was collected only in the hysterectomy group of myoma. This study was approved by the Institutional Review Board-Human Research Committee at Uijeongbu St. Mary’s Hospital (No. UC14TISI0087).

2. **Study methods**

1) Reverse transcriptase-polymerase chain reaction (RT-PCR)

Normal myometrium, endometrium, uterine myoma, and adenomyosis tissues were subjected to RT-PCR to determine the Müllerian inhibiting substance type II receptor (MISRII) mRNA expression levels.

1. RNA extraction and reverse transcription

Tissues for RNA analysis were immediately snap frozen in CryoTubes (Nunc, Roskilde, Denmark) and stored in liquid nitrogen until further processing. Total RNA was extracted from tissues using TRIZOL LS Reagent (Invitrogen, Carlsbad, CA, USA) and RT-PCR was conducted to synthesize cDNA from RNA with the cDNA Synthesis Kit (Takara Korea Biomedical Inc., Seoul, Korea). The polymerase chain reaction (PCR) mixture consisted 4 µL of 5×PCR buffer, 1 µL of Moloney murine leukemia virus reverse transcriptase, 1 µL of dNTP mix, 2 µL of random primers, 1 µL of RNase inhibitor, 2 µg of RNA, and diethyl dicarbonate water in a total volume of 20 µL. Amplification started with the DNA thermal cycler at 25°C for 10 minutes, followed by 42°C for 60 minutes, and 70°C for 10 minutes. The PCR products were stored at −20°C.

2. RT-PCR

cDNA products were amplified using Premix Taq (Takara Ex Taq version; Takara Korea Biomedical Inc.). The PCR mixture consisted of 10 µL of PCR premix, 1 µL of downstream primer (10 pmol), 1 µL of upstream primer (10 pmol), 1 µL of reverse transcribed cDNA, and RNase free sterile water in a total vol-
Shin Young Kim, et al. MIS/AMHRII in myoma and adenomyosis

The PCR primer sequences were: sense primer 5'-CCCTGCA-TACAGCAGAAC-3' (MISRII cDNA; Gene Bank accession no. AF172932; sequence 581–600), and anti-sense primer 5’-TGGGCTCAAGTAGTGGCAGAC-3’ (sequence 921–941). The PCR products (10 µL) were separated by 1.5% agarose gel electrophoresis, and the band size (361 bp) was compared with a DNA ladder.

2) Immunohistochemistry
Paraffin embedded tissue was sliced to a 4 µm thickness and attached to a ProbeOn Plus microscopic slide (Fisher Scientific, Pittsburgh, PA, USA). Tissues for immunohistochemical detection of MISRII were processed using the capillary tube method, a fast temperature-controlled machine, and the microprobe immunostaining station (Biomeda Co., Foster City, CA, USA). The immunostaining procedure was as follows: the slides were preheated at 85°C for 30 minutes, deparaffinized 3 times with xylene for 5 minutes at room temperature, and dehydrated in a graded alcohol series. The slides were auto-claved at 121°C for 10 minutes in citrate buffer for antigen retrieval (Invitrogen) and cooled for 20 minutes at room temperature. After four washes in phosphate buffered saline (PBS), the slides were stained using the Histostain-Plus AEC kit (Invitrogen). After treatment with peroxidase to block non-specific protein binding followed by a wash in PBS, 10% goat non-immune serum was added for 60 minutes. The slides were incubated with rabbit polyclonal anti-human MISRII antiserum (provided by Dr. David T. MacLaughlin, Massachusetts General Hospital, Boston, MA, USA) at 4°C overnight. The slides were rinsed 3 times in Tris-buffered saline with 0.1% Tween 20 (T-TBS; LabVision, Fremont, CA, USA) for 5 minutes and incubated with biotinylated anti-rabbit immunoglobulin G (Invitrogen) as the secondary antibody at room temperature for 2 hours. After rinsing in T-TBS, the Streptavidin HRP detection system (Invitrogen) was applied to the slides for 30 minutes to induce the biotin-streptavidin binding reaction. After washing for 5 minutes in T-TBS, the slides were treated with 3-amino-9-ethylcarbazole for 10 minutes at room temperature, counterstained with hematoxylin, and mounted with Clearmount (Invitrogen).

3) Expression scoring system and statistical analysis
All immunostained sections were reviewed and scored independently by 2 pathologists in a blinded manner without knowledge of the clinicopathological information by considering staining intensity and the percentage of positively stained cells. The total number of cells and cells stained at each intensity were counted in each of 5 fields. Staining intensity greater than that seen in normal follicular granulosa cells was determined to be positive. The frequency of positively stained cells from 5 areas under a high magnification field were calculated as a percentage. Frequencies <30% were weakly positive, 30%–60% was moderately positive, and >60% was strongly positive. Negative was scored as 0, weakly positive as 1, moderately positive as 2, strongly positive as 3. Data were analyzed by the Kruskal-Wallis and Tukey’s tests using ranks. A P<0.05 was considered statistically significant.

Results
1. Expression of MIS/AMHRII mRNA by RT-PCR
The MIS/AMHRII mRNA expression levels in uterine myometrium, endometrium, uterine myoma, and adenomyosis tissues were examined by RT-PCR. In all tissues, a band of the same 361 bp as a part (581–941) of the human MIS/AMHRII cDNA sequence (MISRII cDNA; Gene Bank Accession No. AF172932) was detected. MIS/AMHRII mRNA expression was stronger in uterine myoma than that in uterine myometrium (4.51±0.26 vs. 0.08±0.09; P<0.05). Similarly, the MIS/AMHRII mRNA expression level in adenomyosis was higher, compared with that in normal endometrial tissue (6.84±0.20 vs. 1.63±0.06; P<0.05) (Fig. 1).

2. Expression of MIS/AMHRII protein by immunohistochemistry
The frequencies of MIS/AMHRII expressing cells were 3.15% ±1.69% in normal uterine myometrium, 51.95%±13.96% in uterine myoma, 31.10%±7.19% in endometrium, and 64.65%±4.85% in adenomyosis tissue (Table 1). The most representative light micrographic findings of the myometrium, myoma, endometrium, and adenomyosis are presented in Fig. 2. The liver appeared to be MIS/AMHRII negative (negative control, Fig. 2A). The multiple layered granulosa cells of prean- tral follicle in ovary showed strong expression for MIS/AMHRII (positive control, Fig. 2B). Myometrium expressed little or no
MIS/AMHRII (Fig. 2C), whereas in myoma, expression of MIS/
AMHRII was strong (Fig. 2D). Endometrium showed moderate
expression for
MIS/AMHRII (Fig. 2E), but adenomyosis showed
strong expression (Fig. 2F). The mean intensity scores for
MIS/
AMHRII expression were 0.13±0.07, 2.08±0.56, 1.24±0.29,
and 2.59±0.19 in uterine myometrium tissue, uterine myoma
endometrial tissue and adenomyosis tissue, respectively
(Table 1, Fig. 3). MIS/AMHRII expression was higher in uterine
myoma and adenomyosis tissues than that in normal uterine
muscle and endometrial tissue, respectively.

Discussion

MIS/AMH has long been known to be produced in immature
Sertoli cells in male embryos and binds to MIS/AMH receptors
in primordial Müllerian ducts to cause regression of female
reproductive structures [11]. Similar to other members of the
TGF-β family, MIS/AMH binds to a serine-threonine kinase
receptor complex of type I and II. Type II receptor, which is the
primary receptor binds the ligand. Activin receptor-like kinase
(ALK)-2, ALK-3 and ALK-6 serve as type I receptor for MIS/
AMH. Both types are required for MIS/AMH signaling [3,11].

Several studies have demonstrated that MIS/AMH not only
plays a significant role in embryonic sexual development, but
also causes the growth inhibition in cells expressing MIS/AMH
receptors. Since most gynecologic tumors originate from Mülle-
rian duct derived tissues and MIS/AMH causes regression of the
Müllerian duct, it is expected to inhibit the growth of the gy-
 necologic tumors via MIS/AMH receptor-mediated mechanism
[3,11]. Furthermore, several lines of evidence suggest that MIS/
AMH inhibits proliferation in tissues and cell lines of MIS/AMH
receptor-expressing gynecologic malignancies such as ovarian
cancer [12-17], cervical cancer [18-21], and endometrial cancer
[22,23]. In vitro studies using human epithelial ovarian cancer
cell line (OVCAR 8) revealed that MIS/AMH inhibits growth of
epithelial ovarian cancer cells [14,17]. Park et al. [13] reported
that MIS/AMH inhibits growth of ovarian cancer by deregulat-
ing the Wnt signal pathway via the β-catenin interacting pro-
tein. Similarly, MIS/AMHRII is also present in normal cervical and

Table 1. Frequency and intensity of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor (MIS/AMHRII) in myometrium, myoma, endometrium, and adenomyosis

| Pathology   | Myometrium | Myoma  | Endometrium | Adenomyosis |
|-------------|------------|--------|-------------|-------------|
| Frequency (%) | 3.15±1.69  | 51.95±13.96 | 31.10±7.19  | 64.65±4.85  |
| Intensity score | 0.13±0.07  | 2.08±0.56  | 1.24±0.29  | 2.59±0.19  |

Data are mean±standard deviation for continuous variables.
Shin Young Kim, et al. MIS/AMHRII in myoma and adenomyosis

cervical cancer tissues, and MIS inhibits proliferation of cervical cells in vitro [19,20]. MIS/AMH-mediated growth suppression is also observed in the C33A cervical cancer cell line [21]. MIS/AMHRII is highly expressed in a human endometrial cancer cell line (AN3CA), where MIS/AMH functions as a tumor suppressor by regulating signaling pathways that could contribute to endometrial carcinogenesis [23].

Myoma is the most common benign tumor of the female reproductive tract and is a monoclonal tumor arising from the smooth muscle tissue of the uterine myoma [25,26]. Patients usually do not complain of any symptoms, but typical symptoms can be excessive menstrual bleeding, anemia, and chronic pelvic pain, and some women may be subfertile [28]. Treatments for uterine leiomyoma include medications, surgery, and radiologically guided intervention. Of these, surgical treatment includes myomectomy and hysterectomy. Myomectomy has the advantage of preserving the uterus, but the remaining, tiny or deeply embedded leiomyoma is likely to be growing and shown later, requiring another surgery. Therefore, the most effective treatment for myoma is hysterectomy [29]. Medical treatments include levonorgestrel-releasing intrauterine devices, gonadotropin-releasing hormone analogues, selective progesterone receptor modulators, oral contraceptives, progestins, and danazol [29]. However, these treatments do not eliminate

Fig. 2. Light photomicrographs of human (A) liver (negative control), (B) granulosa cells of preantral follicle in the ovary (positive control), (C) myometrium, (D) myoma, (E) endometrium, and (F) adenomyosis. Each image shows the expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor (MIS/AMHRII) in the cell membrane. Right lower boxed area is of higher magnification (×400). Chromogen, amino ethyl carbazol. Magnification (×200).
the tumor and the symptoms recur when treatment is discontinued [28,29].

Adenomyosis is a disease in which the endometrial glandular and stromal cells are invaded locally or diffusely in the myometrium, and the uterus is generally enlarged [27]. Most patients are asymptomatic, but typical symptoms are abnormal uterine bleeding, dysmenorrhea, and infertility [30]. Medical treatments include a levonorgestrel-releasing intrauterine system and gonadotropin-releasing hormone analogues. Surgical treatment includes hysterectomy and conservative surgery [30]. Without any consensus until now, hysterectomy and levonorgestrel-releasing intrauterine devices are still the main stream treatment for adenomyosis [30].

Although uterine leiomyoma and adenomyosis are common diseases in women of childbearing age, the most definite treatment for both diseases is a hysterectomy [29,30]. Thus, various treatments for preserving the uterus, such as uterine artery occlusion by embolization are emerging; however, it is unclear how they affect fecundity and pregnancy [29].

Uterine leiomyoma and adenomyosis are tumors arising from the uterus which originates from the Müllerian duct. Therefore MIS/AMH is expected to inhibit the growth of these benign tumors via MIS/AMH receptor-mediated mechanism. However, unlike ovarian cancer, cervical cancer, and endometrial cancer, little is known about MIS/AMHRII expression or the effect of MIS/AMH.

In this study, we examined MIS/AMHRII expression in uterine leiomyoma and adenomyosis by using RT-PCR and immunohistochemistry. The level of MIS/AMHRII mRNA expression in uterine myomata was higher than that in normal myometrium (4.51±0.26 vs. 0.08±0.09; P<0.05) and it was also stronger in adenomyosis than that in normal endometrial tissue (6.84±0.20 vs. 1.63±0.06; P<0.05). Myoma and adenomyosis showed stronger immunohistochemical expression for the MIS/AMHRII protein also.

We have demonstrated that myoma and adenomyosis express the MIS/AMHRII. The presence of the MIS/AMHRII in these cells identifies them as potential targets for MIS/AMH. MIS/AMHRII expression in myoma and adenomyosis was stronger than that in normal myometrium and endometrium. Our results suggest that MIS/AMH may act on myoma and adenomyosis to inhibit MIS/AMH-mediated cell growth and that MIS/AMH can be used as a uterus preserving treatment for patients with myoma and adenomyosis.

This study is significant as it is the first research to show that myoma and adenomyosis can be targets of MIS/AMH. However, it is unknown whether the receptor is functional or not. Thus, in vitro and in vivo studies are required to further investigate whether MIS/AMH can actually inhibit growth of myoma and adenomyosis.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Rey R, Lukas-Croisier C, Lasala C, Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol 2003;211:21-31.

2. He WW, Gustafson ML, Hirobe S, Donahoe PK. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn 1993;196:133-42.

3. MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance: a potential nontoxic, naturally occurring therapeutic agent for certain human cancers. In: Jakowlew SB, editor. Transforming growth factor-β in cancer
4. Kim JH. Müllerian inhibiting substance: physiology and clinical applications. J Womens Med 2009;2:45-7.
5. Lee HB, Jung YJ, Kim MJ, Cho HH, Kim MR, Kim EJ, et al. Expression of Müllerian Inhibiting Substance (MIS) and its receptor in female genital tract. World J Pathol 2013;2:14-24.
6. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005;20:923-7.
7. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, et al. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 1990;70:16-22.
8. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81:571-6.
9. Chin TW, Parry RL, Donahoe PK. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 1991;51:2101-6.
10. Fuller AF Jr, Krane IM, Budzik GP, Donahoe PK. Müllerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol 1985;22:135-48.
11. Kim JH, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/anti-Müllerian hormone: a novel treatment for gynecologic tumors. Obstet Gynecol Sci 2014;57:343-57.
12. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 2002;8:2640-6.
13. Park SH, Chung YJ, Song JY, Kim SI, Pépin D, MacLaughlin DT, et al. Müllerian inhibiting substance inhibits an ovarian cancer cell line via b-catenin interacting protein deregulation of the Wnt signal pathway. Int J Oncol 2017;50:1022-8.
14. Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mülleriian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99.
15. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, et al. Müllerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 2000;275:37101-9.
16. Song JY, Chen KY, Kim SY, Kim MR, Ryu KS, Cha JH, et al. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol 2009;34:1583-91.
17. Nam SW, Jo YS, Eun JW, Song JY, Ryu KS, Lee JY, et al. Identification of large-scale characteristic genes of Müllerian inhibiting substance in human ovarian cancer cells. Int J Mol Med 2009;23:589-96.
18. Wang JJ, Roffler SR, Chou HH, Yin FY, Yin CS. Characterization of müllerian inhibiting substance binding on cervical carcinoma cells demonstrated by immunocytochemistry. Tissue Cell 1994;26:467-76.
19. Song JY, Jo HH, Kim MR, Lew YO, Ryu KS, Cha JH, et al. Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer. Int J Oncol 2012;40:2013-21.
20. Hwang SJ, Suh MJ, Yoon JH, Kim MR, Ryu KS, Nam SW, et al. Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells. Int J Oncol 2011;39:811-20.
21. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Müllerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A 2003;100:15601-6.
22. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. Endometrial cancer is a receptor-mediated target for Müllerian Inhibiting Substance. Proc Natl Acad Sci U S A 2005;102:111-6.
23. Chung YJ, Kim HJ, Park SH, Yoon JH, Kim MR, Nam SW, et al. Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesis. Int J Oncol 2015;46:2039-46.
24. Namkung J, Song JY, Jo HH, Kim MR, Lew YO, Donahoe PK, et al. Müllerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. J Clin Endocrinol Metab 2012;97:3224-30.
25. Parker WH. Etiology, symptomatology, and diagnosis of
uterine myomas. Fertil Steril 2007;87:725-36.
26. Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344-55.
27. Yen CF, Huang SJ, Lee CL, Wang HS, Liao SK. Molecular characteristics of the endometrium in uterine adenomyosis and its biochemical microenvironment. Reprod Sci 2017;24:1346-61.
28. Pérez-López FR, Ornat L, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, et al. EMAS position statement: management of uterine fibroids. Maturitas 2014;79:106-16.
29. Vilos GA, Allaire C, Laberge PY, Leyland N, Vilos AG, Murji A, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2015;37:157-78.
30. Farquhar C, Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:603-16.